a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline. Eighty-four biopharmaceuticals are now in general medical use (see Table 1).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback